There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Forte Biosciences (FBRX – Research Report) and Alcon (ALC – Research Report) with bullish sentiments.
Invest with Confidence:
Forte Biosciences (FBRX)
Forte Biosciences received a Buy rating from TD Cowen analyst Yaron Werber today. The company’s shares closed last Friday at $15.60.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 8.0% and a 48.4% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Forte Biosciences.
See Insiders’ Hot Stocks on TipRanks >>
Alcon (ALC)
In a report released today, Graham Doyle from UBS maintained a Buy rating on Alcon, with a price target of CHF95.00. The company’s shares closed last Friday at $84.37.
Doyle has an average return of 2.2% when recommending Alcon.
According to TipRanks.com, Doyle is ranked #8500 out of 9284 analysts.
Currently, the analyst consensus on Alcon is a Strong Buy with an average price target of $100.03, which is a 18.3% upside from current levels. In a report issued on January 10, Redburn Atlantic also upgraded the stock to Buy with a CHF93.00 price target.
Read More on FBRX: